PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17068344-4	2006	Based on data obtained using transfected HEK293 and RBL cells, C5L2 is additionally proposed as a functional receptor for C3a and C3a-des-Arg(77).	des-arg	134-141	complement C3	Homo sapiens	130-133	
16879155-9	2006	The very high levels of C3a des-Arg in US plasma could possibly have an additional effect, through priming platelet activation after transfusion.	des-arg	28-35	complement C3	Homo sapiens	24-27	
12540846-4	2003	Here we demonstrate that C5L2 binds the metabolites of C4a and C3a, C4a des-Arg(77), and C3a des-Arg(77) (also known as the acylation-stimulating protein or ASP) at a site distinct from the C5a binding site.	des-arg	93-100	complement C3	Homo sapiens	89-92	
12540846-6	2003	C3a des-Arg(77)/ASP and C3a can potently stimulate triglyceride synthesis in human skin fibroblasts and 3T3-L1 preadipocytes.	des-arg	4-11	complement C3	Homo sapiens	0-3	
12540846-8	2003	This is the first demonstration of the expression of C5L2 in cells that bind and respond to C3a des-Arg(77)/ASP and C3a.	des-arg	96-103	complement C3	Homo sapiens	92-95	
12540846-9	2003	Thus C5L2, a promiscuous complement fragment-binding protein with a high affinity site that binds C3a des-Arg(77)/ASP, may mediate the acylation-stimulating properties of this peptide.	des-arg	102-109	complement C3	Homo sapiens	98-101	
8929866-6	1996	PAF release was represented by significantly reduced inhibiting capacity (58% of normal human plasma, p < 0.01) and complement activation by higher median plasma C3a des-Arg concentrations (1680 ng/mL versus 325 ng/mL in the reference group, p < 0.001).	des-arg	169-176	complement C3	Homo sapiens	165-168	
6604123-0	1983	Human platelet activation by C3a and C3a des-arg.	des-arg	41-48	complement C3	Homo sapiens	37-40	
2293362-2	1990	We studied the possibility that the complement activation product C3a des-Arg is trapped within the coronary circulation during reperfusion of the ischemic myocardium.	des-arg	70-77	complement C3	Homo sapiens	66-69	
2293362-6	1990	Following reperfusion for 5 min, C3a des-Arg was 1284 +/- 232 ng/ml in arterial and 1106 +/- 100 in coronary sinus blood, a significant difference (p less than 0.05).	des-arg	37-44	complement C3	Homo sapiens	33-36	
2293362-7	1990	The amount of C3a des-Arg trapped in the heart at 5-min reperfusion showed positive correlation with its arterial concentration (p less than 0.05).	des-arg	18-25	complement C3	Homo sapiens	14-17	
3501427-0	1987	Solution conformation of carboxy-terminal fragments of the third component of human complement C3: proton nuclear magnetic resonance study of C3a, des-Arg-C3a, and C3a Arg69.	des-arg	147-154	complement C3	Homo sapiens	84-97	
3501427-0	1987	Solution conformation of carboxy-terminal fragments of the third component of human complement C3: proton nuclear magnetic resonance study of C3a, des-Arg-C3a, and C3a Arg69.	des-arg	147-154	complement C3	Homo sapiens	155-158	
3501427-0	1987	Solution conformation of carboxy-terminal fragments of the third component of human complement C3: proton nuclear magnetic resonance study of C3a, des-Arg-C3a, and C3a Arg69.	des-arg	147-154	complement C3	Homo sapiens	155-158	
3501427-2	1987	The intact C3a was used along with des-Arg-C3a, which is formed on cleavage of Arg-77 at the C terminal of C3a, and C3a Arg69, which is a 69-residue fragment produced on tryptic digestion of C3.	des-arg	35-42	complement C3	Homo sapiens	43-46	
3501427-2	1987	The intact C3a was used along with des-Arg-C3a, which is formed on cleavage of Arg-77 at the C terminal of C3a, and C3a Arg69, which is a 69-residue fragment produced on tryptic digestion of C3.	des-arg	35-42	complement C3	Homo sapiens	43-46	
3501427-2	1987	The intact C3a was used along with des-Arg-C3a, which is formed on cleavage of Arg-77 at the C terminal of C3a, and C3a Arg69, which is a 69-residue fragment produced on tryptic digestion of C3.	des-arg	35-42	complement C3	Homo sapiens	43-46	
6604123-6	1983	Further C3a and C3a des-arg exhibited synergism with ADP of equal significance in both aggregation and the release reaction.	des-arg	20-27	complement C3	Homo sapiens	16-19	
35452398-8	2022	Elevated C3a-des-Arg, C4a-des-Arg and C5a, lower C1-inhibitor, and unchanged C3 and C4 were reported immediately post-laboratory based exercise, compared to baseline.	des-arg	13-20	complement C3	Homo sapiens	9-12	
3878728-1	1985	A proton nuclear magnetic resonance (NMR) study is reported of des-Arg-C3a, which is a 76-residue fragment obtained from the N-terminal portion of the alpha chain of the third component of human complement.	des-arg	63-70	complement C3	Homo sapiens	71-74	
3878728-11	1985	Comparisons of the results obtained with those for des-Arg-C3a demonstrate that upon cleavage of C3a very little change, if any, is induced in microenvironments of His-67 and His-72 and a piece of segment that contains His-72 is exposed to solvent and highly flexible.	des-arg	51-58	complement C3	Homo sapiens	59-62	
6604123-5	1983	C3a and C3a des-arg were equally reactive in mediating platelet aggregation and release of serotonin.	des-arg	12-19	complement C3	Homo sapiens	8-11	
29181954-8	2017	The 2 peaks were identified as Complement C3 peptide fragments: C3f and C3f Des-Arg.	des-arg	76-83	complement C3	Homo sapiens	31-44	
23360681-3	2013	The results show that, when incubated with human sera, unfunctionalized GO adsorbs a significant amount of serum proteins and strongly induces complement C3 cleavage (part of the complement activation cascade), generating C3a/C3a(des-Arg), an anaphylatoxin involved in local inflammatory responses, whereas PEGylated nano-GO (nGO-PEG) exhibits dramatic reductions in both protein binding in general and complement C3 activation.	des-arg	230-237	complement C3	Homo sapiens	143-156	
23360681-5	2013	Further mass spectrometry analysis identifies six nGO-PEG binding proteins, four of which are immune-related factors, including C3a/C3a(des-Arg).	des-arg	136-143	complement C3	Homo sapiens	128-131	
23360681-5	2013	Further mass spectrometry analysis identifies six nGO-PEG binding proteins, four of which are immune-related factors, including C3a/C3a(des-Arg).	des-arg	136-143	complement C3	Homo sapiens	132-135	
23360681-6	2013	A series of Western blot analysis demonstrate that nGO-PEG binds up to 2-fold amount of C3a/C3a(des-Arg) than unfunctionalized GO, and can efficiently decrease the level of C3a/C3a(des-Arg) in treated sera, preventing the normal interaction of C3a with its receptor.	des-arg	96-103	complement C3	Homo sapiens	88-91	
23360681-6	2013	A series of Western blot analysis demonstrate that nGO-PEG binds up to 2-fold amount of C3a/C3a(des-Arg) than unfunctionalized GO, and can efficiently decrease the level of C3a/C3a(des-Arg) in treated sera, preventing the normal interaction of C3a with its receptor.	des-arg	96-103	complement C3	Homo sapiens	92-95	
23360681-6	2013	A series of Western blot analysis demonstrate that nGO-PEG binds up to 2-fold amount of C3a/C3a(des-Arg) than unfunctionalized GO, and can efficiently decrease the level of C3a/C3a(des-Arg) in treated sera, preventing the normal interaction of C3a with its receptor.	des-arg	96-103	complement C3	Homo sapiens	92-95	
23360681-6	2013	A series of Western blot analysis demonstrate that nGO-PEG binds up to 2-fold amount of C3a/C3a(des-Arg) than unfunctionalized GO, and can efficiently decrease the level of C3a/C3a(des-Arg) in treated sera, preventing the normal interaction of C3a with its receptor.	des-arg	96-103	complement C3	Homo sapiens	92-95	
23360681-6	2013	A series of Western blot analysis demonstrate that nGO-PEG binds up to 2-fold amount of C3a/C3a(des-Arg) than unfunctionalized GO, and can efficiently decrease the level of C3a/C3a(des-Arg) in treated sera, preventing the normal interaction of C3a with its receptor.	des-arg	96-103	complement C3	Homo sapiens	92-95	
23360681-6	2013	A series of Western blot analysis demonstrate that nGO-PEG binds up to 2-fold amount of C3a/C3a(des-Arg) than unfunctionalized GO, and can efficiently decrease the level of C3a/C3a(des-Arg) in treated sera, preventing the normal interaction of C3a with its receptor.	des-arg	181-188	complement C3	Homo sapiens	88-91	
23360681-7	2013	In a proof-of-concept experiment, we demonstrate that nGO-PEG may serve to help eliminate the C3a/C3a(des-Arg) induced by other nanomaterials such as as-made GO, indicating a new strategy to modulate the immune responses evoked by one nanomaterial through the addition of another type of nanomaterial.	des-arg	102-109	complement C3	Homo sapiens	94-97	
23360681-7	2013	In a proof-of-concept experiment, we demonstrate that nGO-PEG may serve to help eliminate the C3a/C3a(des-Arg) induced by other nanomaterials such as as-made GO, indicating a new strategy to modulate the immune responses evoked by one nanomaterial through the addition of another type of nanomaterial.	des-arg	102-109	complement C3	Homo sapiens	98-101